Genital condylomata in a patient receiving infliximab for Crohn's disease.
Infliximab is a monoclonal antibody against tumour necrosis factor-alpha. Recent studies have shown that it is effective in treating patients with refractory Crohn's disease and in those with Crohn's fistulae. Though this drug is found to be safe in clinical trials, sporadic reports of serious complications have been recorded in the literature. The case of a patient who developed profuse genital warts after infliximab treatment is reported. The literature is reviewed and information is presented on side effects and complications as a result of infliximab therapy.
Somasekar
A
A
Department of Gastroenterology, Royal Glamorgan Hospital, Llantrisant, UK.
Alcolado
R
R
D000328:Adult; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D003092:Colitis / Q000188:drug therapy; D003218:Condylomata Acuminata / Q000139:chemically induced*; D003424:Crohn Disease / Q000188:drug therapy*; D005765:Gastrointestinal Agents / Q000009:adverse effects*; D006801:Humans; D007079:Ileitis / Q000188:drug therapy; D000069285:Infliximab; D008297:Male; D010409:Penile Diseases / Q000139:chemically induced*; D010502:Perineum
D000911:Antibodies, Monoclonal; D005765:Gastrointestinal Agents; D000069285:Infliximab